A5000418022- Glioma Diagnosis and Treatment
- Meningioma and schwannoma management
- Neuroblastoma Research and Treatments
- Brain Metastases and Treatment
- Pituitary Gland Disorders and Treatments
- Neurofibromatosis and Schwannoma Cases
- Neuroendocrine Tumor Research Advances
- Muscle Physiology and Disorders
- Inflammatory Myopathies and Dermatomyositis
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Chromatin Remodeling and Cancer
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Microtubule and mitosis dynamics
- Cardiomyopathy and Myosin Studies
- Growth Hormone and Insulin-like Growth Factors
- CNS Lymphoma Diagnosis and Treatment
- Vascular Malformations Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Epigenetics and DNA Methylation
- Genetic Neurodegenerative Diseases
- Bone Tumor Diagnosis and Treatments
- Cancer Cells and Metastasis
- Ocular Oncology and Treatments
Institut de Neurophysiopathologie
2016-2025
Centre National de la Recherche Scientifique
2012-2025
Hôpital de la Timone
2016-2025
Aix-Marseille Université
2016-2025
Inserm
2011-2024
Centre de Recherche en Cancérologie de Lyon
2022-2024
Centre Léon Bérard
2009-2024
Royal Children's Hospital
2021-2024
Université Claude Bernard Lyon 1
2012-2024
Freie Universität Berlin
2024
Major discoveries in the biology of nervous system tumors have raised question how non-histological data such as molecular information can be incorporated into next World Health Organization (WHO) classification central tumors. To address this question, a meeting neuropathologists with expertise diagnosis was held Haarlem, Netherlands, under sponsorship International Society Neuropathology (ISN). Prior to meeting, participants solicited input from clinical colleagues diverse...
cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches CNS Tumor Taxonomy) was established evaluate make practical recommendations on recent advances in the field of tumor classification, particularly light rapid progress molecular insights into these neoplasms. For Round 2 its deliberations, Working Committee 3 reconstituted convened Utrecht, The Netherlands, for a meeting designed review putative new types advance any future World Health Organization classification. In...
To compare event-free survival (EFS), overall (OS), pattern of relapse, and hearing loss in children with standard-risk medulloblastoma treated by postoperative hyperfractionated or conventionally fractionated radiotherapy followed maintenance chemotherapy.In all, 340 age 4 to 21 years from 122 European centers were postoperatively staged randomly assigned treatment (HFRT) standard (conventional) (STRT) a common chemotherapy regimen consisting eight cycles cisplatin, lomustine,...
Histopathological grading of ependymoma has been controversial with respect to its reproducibility and clinical significance. In a 3-phase study, we reviewed the pathology 229 intracranial ependymomas from European trial cohorts infants (2 trials - SFOP/CNS9204) older children AIEOP/CNS9904) assess both diagnostic concordance among five neuropathologists prognostic utility histopathological variables, particularly tumor grading.In phase 1, using WHO criteria without first discussing any...
Abstract Purpose: Our objective was to identify the genetic changes involved in primary central nervous system lymphoma (PCNSL) oncogenesis and evaluate their clinical relevance. Experimental Design: We investigated a series of 29 newly diagnosed, HIV-negative, PCNSL patients using high-resolution single-nucleotide polymorphism (SNP) arrays (n = 29) whole-exome sequencing 4) approaches. Recurrent homozygous deletions somatic gene mutations found were validated by quantitative real-time PCR...
The 2016 World Health Organization (WHO) classification of central nervous system tumors stratifies isocitrate dehydrogenase (IDH)-mutant gliomas into 2 major groups depending on the presence or absence 1p/19q codeletion. However, grading remains unchanged and it is now controversial whether can be still applied to this updated molecular classification.In a large cohort 911 high-grade IDH-mutant from French national POLA network (including 428 without codeletion 483 anaplastic...
The HERBY trial was a phase II open-label, randomized, multicenter evaluating bevacizumab (BEV) in addition to temozolomide/radiotherapy patients with newly diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3 and 18 years. We carried out comprehensive molecular analysis integrated pathology, radiology, immune profiling. In post-hoc subgroup analysis, hypermutator tumors (mismatch repair deficiency somatic POLE/POLD1 mutations) those biologically resembling pleomorphic...
Abstract In the 5th edition of WHO CNS tumor classification (CNS5, 2021), multiple molecular characteristics became essential diagnostic criteria for many additional types. For those tumors, an integrated, “histomolecular” diagnosis is required. A variety approaches exists determining status underlying markers. The present guideline focuses on methods that can be used assessment currently most informative and prognostic markers gliomas, glioneuronal neuronal tumors. main are systematically...
Pilocytic astrocytomas (PA) are Grade I brain tumors characterized by an excellent prognosis. In some cases, however, the patient has a bad outcome. The aim of our study was to search for clinicopathological factors underlying prognosis patients with this disease.We reviewed clinical, neuroradiological, and histopathological features 80 PAs (33 cerebellar, 18 optochiasmatic, 16 brainstem, 7 spinal cord, 3 thalamic, 2 optic nerve, 1 hemispheric) in pediatric patients.Pathological examination...
Objective: To describe the phenotypic spectrum of dysferlin (DYSF) gene mutations (which cause dysferlinopathies, autosomal recessive muscular dystrophies) in patients with a protein deficiency.Design: Clinical, biological, and pathological data from 40 were reviewed.The diagnosis dysferlinopathy was based on absence or strong reduction muscle, confirmed by mutational screening DYSF gene.Setting: Two French neuromuscular diseases centers (in Paris Marseilles).Results: main phenotypes are...
Negative feedback regulation of the proopiomelanocortin (POMC) gene by glucocorticoid (Gc) receptor (GR) is a critical feature hypothalamo-pituitary-adrenal axis, and it in part exerted trans-repression between GR orphan nuclear receptors related to NGFI-B. We now show that Brg1, ATPase subunit Swi/Snf complex, essential for this Brg1 required vivo stabilize interactions NGFI-B as well HDAC2. Whereas constitutively present at POMC promoter, recruitment HDAC2 ligand-dependent results histone...
Patients affected by the multiple endocrine neoplasia type I syndrome (MEN1) display a high incidence of pituitary adenomas, though it is still unknown whether these tumors have specific pathologic features that would distinguish them from sporadic adenomas. Pituitary tissue specimens 77 MEN1 patients GTE (Groupe d'étude des Tumeurs Endocrines) register were compared with unselected 2509 non-MEN1 and also to control subgroup 296 cases, where 1 tumor was matched 4 same hormonal immunoprofile....
To date only 18 patients with aggressive pituitary tumors or carcinomas treated temozolomide have been reported. Increased expression of O6-methylguanine-DNA-methyltranferase (MGMT) has suggested to predict resistance temozolomide.The objective the study was describe antitumoral efficacy and toxicity in evaluate possible prognostic value MGMT promoter methylation protein expression.Eight patients, five (three prolactin (PRL) two ACTH) three (one PRL ACTH), all administered orally for four 24...
Abstract Purpose: Germline hSNF5/INI1 mutations are responsible for hereditary cases of rhabdoid tumors (RT) that constitute the predisposition syndrome (RPS). Our study provides first precise overview prevalence RPS within a large cohort RT. Experimental Design: coding exons were investigated by sequencing and multiplex ligation-dependent probe amplification. Results: Seventy-four constitutional DNAs from 115 apparently sporadic RT analyzed 1999 to 2009. found in 26 patients (35%). Data 9...